A sound medication decision starts with a reliable history: what a person actually takes, why, how, and what has changed. This guide teaches you to connect that history with symptoms, laboratory results, comorbidities, treatment goals, and patient preferences before choosing or revising therapy. You will work through clinical priorities such as anticoagulation, diabetes, respiratory disease, infections, pain, and adverse effects, then carry decisions through prescription validation, product selection, calculations, labelling, and follow-up. It also covers how to judge evidence, explain risk clearly, communicate across care settings, and handle privacy, consent, incidents, and scope questions. Examples use Canadian SI units and focus on pharmacist judgment in best-answer MCQ scenarios.
Providing Care: Clinical Care
1. Build the actual medication history
A medication history describes what the patient actually uses, not merely what was prescribed or last dispensed. Start with an open question, then ask about each prescription medicine, non-prescription product, supplement, inhaler, injection, and product used only when needed. Record the name, strength, dose, route, frequency, last use, and reason for use. Compare the interview with another source, such as dispensing records or a labelled container. A refill record shows access to a medicine, but cannot prove ingestion. When sources differ, ask when and why use changed; do not silently replace the patient's account with the chart. This entry-to-practice competency document identifies a best possible medication history as using at least two sources, including the patient interview. An accurate history is the starting point for judging benefit, harm, and interactions.
Worked example: The chart lists amlodipine 10 mg daily. The patient says they split each tablet and take 5 mg daily because 10 mg caused ankle swelling. They also began a purchased herbal sleep product last week. Record both as reported use, inspect the amlodipine container, identify the herbal ingredients, and check dispensing records. Then assess blood pressure, swelling, and potential interactions using the verified history.
Watch the distinction: A dispensing record is not proof that the prescribed dose was taken. Treating it as the whole history can hide deliberate dose changes and non-prescription exposure.
2. Reconcile medicines across care settings
Medication reconciliation uses the best possible medication history as the comparison point when care changes hands. List what the patient was taking before the transition, then compare each item with the new orders: continued, changed, stopped, or newly started. A difference may be intentional, but an unexplained difference is an unresolved discrepancy. Check discharge notes, reasons for changes, and the patient's understanding. Clarify conflicting instructions with the responsible care team before telling the patient which regimen to follow. Pay particular attention to duplicate therapy, omitted chronic treatment, changed strengths, and products the patient may still have at home. Once clarified, communicate one current list and its change rationale to the patient and next provider. This process prevents both unintended interruption and accidental continuation of a stopped drug. The broader PEBC pharmacist study guide places reconciliation among related care decisions.
Worked example: Before admission, a patient took levothyroxine daily. It is absent from the discharge medication list, yet the signed discharge note says to continue thyroid treatment. Compare the preadmission history and discharge orders, ask whether the patient received levothyroxine in hospital, and contact the discharging team to resolve the conflict. Update the list only after confirming the intended dose and continuation.
Watch the distinction: An omitted drug on one discharge document is not automatically a deliberate stop. Equally, an old home supply is not permission to restart it without resolving conflicting instructions.
3. Recognize urgent symptoms
Symptom assessment begins with onset, severity, course, associated symptoms, and the patient's current condition. New central chest pressure accompanied by sweating, breathlessness, faintness, or nausea can indicate acute cardiac illness even if the patient calls it indigestion. Do not let a request for an antacid narrow the assessment prematurely. Ask enough to recognize the danger, then arrange immediate emergency assessment; a retail consultation cannot exclude a time-sensitive cardiac event. Symptoms that are sudden, severe, progressive, or accompanied by altered consciousness or major breathing difficulty also warrant urgent escalation. For less urgent symptoms, examine duration, triggers, prior episodes, medicines, and functional impact before recommending self-care. The decision is based on the whole presentation and possible cost of delay, not on whether an over-the-counter product might ease one symptom.
Worked example: A 62-year-old asks for an antacid but reports new crushing chest pressure that began 20 minutes ago while resting, with sweating and shortness of breath. These associated features make a cardiac cause plausible. Arrange emergency medical assessment immediately, keep the person supported while help arrives, and pass on the onset and symptoms. Do not trial an antacid to see whether the pressure settles.
Watch the distinction: Improvement after an antacid would not reliably rule out a cardiac problem. Waiting for a self-treatment response can delay assessment of potentially dangerous chest symptoms.
4. Interpret results in context
Interpret a result in four layers: compare it with the supplied laboratory interval, compare it with the patient's earlier results, connect it with symptoms and medicines, and decide how quickly it needs assessment. Potassium can rise when a medicine reduces renal potassium excretion, including medicines that inhibit the renin-angiotensin-aldosterone system. Kidney function, potassium supplements, other medicines, and sample quality also matter. A single unexpectedly high value can reflect a collection problem, but possible artefact should trigger verification, not dismissal. Ask about weakness, palpitations, and new illness; review the timing of medicine changes and renal results. A meaningful upward trend outside the stated interval calls for prompt clinical evaluation because high potassium can disturb cardiac conduction. The pharmacist's task is to connect the result to the patient and coordinate the next safe action.
Worked example: A patient's potassium was 4.1 mmol/L before an angiotensin-converting enzyme inhibitor change and is now 5.8 mmol/L. The laboratory interval is 3.5 to 5.0 mmol/L. The rise is 5.8 − 4.1 = 1.7 mmol/L, and the new result is 0.8 mmol/L above the interval. Review symptoms, kidney function, other potassium-raising products, and sample concerns, and arrange prompt assessment.
Watch the distinction: Reading 5.8 mmol/L without its interval or trend misses the clinical signal. Assuming the result is sample error is also unsafe until the patient and result are assessed.
5. Prioritize medication problems
Medication therapy problems can involve an untreated condition, an ineffective drug or dose, an adverse effect, an interaction, inappropriate use, or a medicine without a valid indication. Classifying the problem helps identify its cause; prioritizing it determines what to do first. Compare the immediacy and severity of potential harm, whether the problem is reversible, and what the patient is experiencing now. Symptomatic hypoglycaemia in a person using insulin can impair judgment and progress rapidly, so it takes priority over a stable, mildly troublesome symptom. After the immediate danger is managed, return to the lower-priority issue rather than losing it. Review why the problem arose, whether therapy needs changing, and who will follow up. The PEBC pharmacist blueprint includes assessment and care planning; it does not supply a fixed ranking for every patient.
Worked example: A patient reports mild reflux most evenings and arrives shaky and confused after taking insulin without lunch. Check glucose and the ability to swallow, respond to the low glucose according to the available care plan, and obtain urgent help if the person cannot safely take oral carbohydrate. Once stable, investigate the missed meal and insulin use. Then assess the reflux pattern and its treatment.
Watch the distinction: The problem mentioned first is not necessarily the priority. Addressing reflux while symptomatic low glucose is still present confuses chronic discomfort with immediate safety risk.
6. Assess blood pressure treatment
A blood pressure decision needs a pattern, a credible measurement method, and an account of what treatment the patient actually takes. Ask about cuff fit, seated rest, timing, repeated readings, and whether measurements were recorded before or after medication. Compare the pattern with the goal specified for that patient rather than reacting to one unusual number. Next, assess adverse effects: dizziness may reflect low pressure at certain times, postural change, dehydration, or another medicine, even when average readings remain high. Stopping treatment can itself explain loss of control. Discuss what made the regimen unacceptable and choose a feasible adjustment with the patient and prescriber as needed. Define what readings and symptoms will be reviewed, and when. An effective drug on paper does not help if the patient cannot tolerate or use it.
Worked example: A case sets a home goal below 135/85 mmHg. Five properly taken readings are about 148/92 mmHg, but the patient stopped the prescribed medicine after feeling dizzy on standing. The repeated readings exceed the case goal; the dizziness still needs assessment. Check seated and standing symptoms, timing, and other medicines, then agree on a tolerable treatment plan and repeat home monitoring.
Watch the distinction: Increasing a dose solely because readings are high ignores why treatment stopped. Conversely, accepting one normal office reading can conceal a sustained high home pattern.
7. Spot worsening heart failure
Heart failure can worsen when the body retains sodium and water, increasing filling pressures and producing breathlessness, swelling, and rapid weight gain. New difficulty breathing while lying flat, waking breathless, or reduced exercise tolerance may reflect congestion. Ask when symptoms began, whether they occur at rest, and whether there is chest pain or severe breathlessness requiring emergency assessment. Compare weights measured on the same scale under similar conditions; the direction and speed of change matter more than an isolated value. Review diuretic use, access to supply, recent medicine changes, kidney function, and possible triggers. A missed diuretic may contribute, but it does not prove the whole cause. The pharmacist should identify likely deterioration, arrange timely clinical assessment, and help restore a workable treatment plan after the cause is understood.
Worked example: A patient with heart failure missed several diuretic doses during a supply gap. Weight rose from 76.0 kg to 78.4 kg over four days, a gain of 2.4 kg. They now sleep propped up and have ankle swelling. The combined trend and symptoms suggest congestion. Assess current breathing severity, arrange timely clinical review, clarify the missed doses, and resolve the supply barrier.
Watch the distinction: A weight increase alone does not diagnose fluid overload. Ignoring new orthopnoea because the patient reports a plausible missed-dose explanation can miss clinically important deterioration.
8. Balance anticoagulation decisions
Anticoagulants reduce clot formation, so their benefit must be considered alongside bleeding risk for the individual patient. Start with the indication, such as stroke prevention in atrial fibrillation, then check actual use, kidney function where relevant, interacting medicines, and signs of bleeding. Black, tarry stools may indicate gastrointestinal bleeding and call for urgent assessment; a routine refill discussion is secondary. Ask about dizziness, weakness, visible bleeding, and use of non-prescription anti-inflammatory medicines, but avoid delaying emergency care with an exhaustive interview. Once immediate safety is addressed, reassess whether the anticoagulant and its regimen remain appropriate. Kidney impairment can increase exposure to some anticoagulants, while drugs that impair haemostasis may increase bleeding without changing anticoagulant concentration. Do not tell a patient with suspected serious bleeding simply to continue routine dosing until a scheduled review.
Worked example: A patient taking an oral anticoagulant for atrial fibrillation requests a refill and reports black, sticky stools since yesterday and new light-headedness. These symptoms could represent gastrointestinal bleeding. Arrange urgent medical assessment and convey the anticoagulant name, last dose, and other medicines. After the acute issue is evaluated, review indication, kidney results, interactions, and the ongoing treatment plan.
Watch the distinction: The need for stroke prevention does not make possible bleeding safe to ignore. A normal-looking refill history cannot rule out active harm from anticoagulant treatment.
9. Prevent recurrent cardiovascular events
After myocardial infarction, distinguish treatment that relieves an episode from treatment intended to lower the chance of another event. A short-acting nitrate relaxes vascular smooth muscle and can relieve angina, but using it when pain occurs does not replace long-term risk reduction. Preventive medicines may address thrombosis, cholesterol, cardiac workload, or adverse remodelling, depending on the patient's indication and tolerance. When a patient stops one, ask why before proposing a fix: adverse effects, cost, misunderstanding, or a deliberate shared decision lead to different responses. Review current symptoms, the discharge plan, contraindications, and what the patient values. Explain the particular preventive purpose of the stopped medicine and arrange an acceptable plan with the care team. Recurring or changing chest pain requires separate assessment. Related decisions can be practised in the PEBC Pharmacist MCQ practice questions.
Worked example: Following myocardial infarction, a patient uses prescribed nitroglycerin for occasional chest discomfort but stopped atorvastatin because of muscle pain. Nitroglycerin may relieve an episode; atorvastatin lowers LDL cholesterol and is intended to reduce future cardiovascular risk. Assess the pain's timing, severity, and other possible causes, then discuss a tolerable preventive plan with the patient and care team. Assess any changing chest symptoms promptly.
Watch the distinction: Feeling better after nitroglycerin does not show that future event risk is controlled. Restarting a stopped preventive medicine without exploring the adverse effect may reproduce non-use.
10. Individualize diabetes therapy
High average glucose and episodes of low glucose can coexist. Before intensifying therapy, separate fasting, meal-related, and overnight readings, then match each pattern to medicine timing, meals, activity, and symptoms. Insulin can keep lowering glucose when food intake falls, so skipped meals may create overnight risk even if other readings are high. Check kidney function because it can alter insulin clearance and the suitability of other diabetes medicines. Ask whether the regimen is manageable and what outcomes matter to the patient, including avoiding severe lows. Resolve immediate hypoglycaemia risk, examine the cause, and then choose changes that address high readings without worsening lows. A single summary measure can conceal dangerous variability. Follow-up should include both glucose patterns and the patient's ability to carry out the revised plan.
Worked example: A patient's daytime glucose readings are often above their agreed range, yet three overnight episodes of sweating coincide with evenings when dinner was skipped after insulin. Treat any current low reading, assess meal and insulin timing, and review the overnight pattern before increasing glucose-lowering treatment. A plan that lowers daytime readings but increases overnight lows would fail the patient's safety goal.
Watch the distinction: High daytime readings do not justify automatic insulin escalation. The pattern may reflect separate daytime and overnight problems that require different changes and follow-up.
11. Respond to hypoglycaemia
Hypoglycaemia may cause tremor, sweating, hunger, confusion, or unusual behaviour in a person using insulin or another glucose-lowering medicine. Confirm glucose when a meter is available, but assess consciousness and swallowing immediately. An alert person who can swallow can use a measured fast-acting carbohydrate according to the stated care plan, followed by a timed glucose recheck. If symptoms persist or glucose remains low, repeat the plan's treatment step and seek appropriate help. A person who is unconscious, seizing, or unable to swallow needs emergency assistance and must not receive food or drink by mouth. Once glucose is stable, identify the cause: missed food, extra medicine, unusual exercise, alcohol, illness, or reduced clearance. Preventing recurrence may require changing the regimen, not merely teaching the rescue step.
Worked example: In a hypothetical care plan, glucose below 4.0 mmol/L triggers 15 g of rapid carbohydrate and a recheck after 15 minutes. An alert patient with tremor measures 3.4 mmol/L and can swallow. Give the specified 15 g, recheck after 15 minutes, and follow the plan if still low. Ask about meals and insulin; the patient reports taking the usual dose but missing lunch.
Watch the distinction: Do not give oral carbohydrate to someone who cannot swallow safely. Also, correcting one reading without finding the missed-meal cause leaves the next episode possible.
12. Separate asthma relief from control
A short-acting beta-2 agonist such as salbutamol relaxes airway smooth muscle and can quickly relieve bronchoconstriction. An inhaled corticosteroid works differently: it suppresses airway inflammation and helps prevent symptoms and exacerbations when used as prescribed. Repeated reliever use and waking at night suggest inadequate control, but first check whether the patient is using the controller, whether the technique delivers medicine to the lungs, and whether symptoms have another cause. Ask about activity limits, recent worsening, and any urgent breathing difficulty. Demonstrate the device, observe the patient's technique, and address barriers such as fear of adverse effects or confusion between inhalers. Then arrange an appropriate controller review and follow-up. Simply renewing more reliever may temporarily ease symptoms while leaving inflammation inadequately treated.
Worked example: A patient uses salbutamol most days and wakes coughing several nights each week. Their prescribed inhaled corticosteroid remains unopened because they thought it was for attacks only. Explain that salbutamol gives rapid relief while the corticosteroid is the regular anti-inflammatory treatment, demonstrate its use, and confirm the patient can repeat the steps. Arrange review of control and any worsening symptoms.
Watch the distinction: Frequent reliever use is not evidence that the reliever alone is sufficient. It may signal poor control, incorrect controller use, poor technique, or a need to reassess treatment.
13. Review COPD treatment and devices
For chronic obstructive pulmonary disease, assess current breathlessness, activity limits, exacerbation history, and how the patient uses each inhaler. Maintenance bronchodilators aim to keep airways more open over time; a rescue inhaler addresses episodic symptoms. Device mechanics matter as much as drug selection. A dry-powder inhaler depends on the patient's inspiratory effort to disperse powder, while other devices have different coordination and preparation demands. Ask the patient to demonstrate loading, exhaling away from the mouthpiece, inhaling, and any device-specific steps. If adequate flow or dexterity is lacking, apparent treatment failure may be poor drug delivery. Consider a device the patient can use and reassess symptoms after correcting technique. New marked breathlessness, altered sputum, fever, or reduced oxygenation may indicate an exacerbation requiring timely clinical assessment.
Worked example: A patient reports no benefit from a dry-powder maintenance inhaler. During demonstration, they inhale weakly and cannot complete the device's required manoeuvre; they also report no recent exacerbations. First correct any teachable steps and assess whether the device remains unsuitable. Discuss an appropriate alternative delivery device with the care team, then check breathlessness and technique again after the change.
Watch the distinction: Persistent symptoms after inhaler use do not prove the molecule is ineffective. The dose may never reach the airways if the patient cannot operate the device.
14. Judge antimicrobial need
An antibiotic decision begins with the likely cause and the expected benefit for this patient. Nasal congestion with a short, mild illness commonly fits a self-limited viral pattern; antibiotics act on bacteria and do not treat viruses. Ask about onset, course, fever, focal symptoms, breathing, immune vulnerability, and available test results. Seek features that would change the probability of a bacterial illness or indicate a complication, rather than treating coloured mucus or patient expectation as proof. If bacterial benefit is unlikely, explain the reasoning, recommend suitable symptom relief, and give clear return precautions for worsening or persistent symptoms. Unnecessary antibiotics expose patients to adverse effects and can promote resistance. If evidence does support bacterial infection, selection still depends on site, likely organism, allergy history, patient factors, and the applicable treatment plan.
Worked example: A patient requests an antibiotic after two days of nasal congestion and mild sore throat. The case describes no fever, focal bacterial findings, or breathing difficulty. The brief, uncomplicated pattern offers little reason to expect antibiotic benefit. Discuss fluids and suitable symptom relief, and advise reassessment if symptoms worsen, breathing becomes difficult, or the illness develops new concerning features.
Watch the distinction: A request for antibiotics or the presence of mucus does not establish bacterial infection. Giving an antibiotic without a plausible target adds risk without a clear benefit.
15. Clarify allergy before selecting therapy
An allergy label is a starting clue, not a complete reaction history. Ask which drug was taken, what happened, how soon symptoms began, whether treatment was needed, and whether the patient later tolerated the same or a related medicine. Hives, swelling, breathing difficulty, or a severe delayed skin reaction raise different concerns from isolated nausea. Nausea is a common adverse effect and does not by itself establish an immune-mediated allergy. Record the reaction in specific terms so future decisions are based on evidence rather than a vague label. Do not erase a historical warning solely from memory if details remain uncertain; seek records when needed. When selecting therapy, weigh the infection being treated, the seriousness of the reported reaction, the time since it occurred, and available alternatives. Unnecessary avoidance can lead to a less suitable antibiotic.
Worked example: The chart says “penicillin allergy.” The patient recalls nausea after an oral course years ago, with no rash, swelling, wheeze, or emergency treatment. Record “nausea after penicillin; no reported immune symptoms” and clarify the exact drug and timing if possible. This history does not prove anaphylaxis. Choose treatment using the actual reaction history and the infection's needs, while preserving uncertainty where details are missing.
Watch the distinction: Calling every unpleasant effect an allergy overstates risk. Conversely, a vague label should not be dismissed without asking about timing, skin findings, breathing, and severity.
16. Choose safer pain treatment
Pain treatment should match the pain source while accounting for the patient's other risks. Oral non-steroidal anti-inflammatory drugs inhibit cyclo-oxygenase and reduce prostaglandin production, which can relieve inflammatory pain. The same mechanism reduces protective gastrointestinal prostaglandins and can contribute to ulceration or bleeding. These drugs can also affect kidney blood flow and interact with medicines that increase bleeding risk. Ask about prior gastrointestinal bleeding, kidney disease, cardiovascular conditions, anticoagulants, current pain severity, and what has already helped. For localized knee pain, exercise or physical therapy, joint supports, and some lower-exposure medicine options may be considered according to the patient's circumstances. The best plan balances expected relief, function, and harm, then defines how benefit and adverse effects will be checked.
Worked example: A patient with previous gastrointestinal bleeding asks for an oral NSAID for knee pain. The prior bleed makes another gastrointestinal event a material concern, especially if other bleeding-risk medicines are present. Ask about pain, function, current drugs, and prior treatments. Discuss exercise-based care and appropriate medication alternatives with the patient and care team, then set a practical measure of pain relief and function for follow-up.
Watch the distinction: An over-the-counter NSAID is not automatically low risk. Focusing only on its analgesic effect can miss a patient's prior bleeding and interacting medicines.
17. Assess antidepressant response
Judge antidepressant response only after understanding how the medicine was used, how long it was used consistently, which symptoms changed, and whether adverse effects or access problems interfered. Sporadic dosing over a short period gives limited evidence about effectiveness. Ask about mood, sleep, functioning, substance use, and the patient's own goals. New suicidal thoughts change the order of decisions: assess immediacy, intent, plan, access to means, and available support, then arrange urgent safety care when indicated. Do not leave the patient with only a routine follow-up plan if immediate risk is possible. After safety is addressed, discuss adherence barriers, tolerability, and whether the medicine or broader treatment plan should change. A patient can need prompt safety support and a later, more careful efficacy assessment at the same time.
Worked example: A patient has taken sertraline only on some days for two weeks, reports no improvement, and says they have begun thinking about suicide. First assess immediate safety and arrange urgent support appropriate to the risk, including emergency help if necessary. The inconsistent, brief exposure does not establish sertraline failure. Once safe, explore why doses were missed and arrange a treatment review with clear follow-up.
Watch the distinction: Labelling an antidepressant ineffective after sporadic early use ignores exposure. More seriously, debating a dose change before addressing new suicidal thoughts reverses the safety priority.
18. Reduce medicine-related falls
A fall may have several medicine-related contributors. Sedatives can slow reaction time and impair balance, especially when the patient rises at night. Blood-pressure-lowering medicines can cause dizziness on standing if cerebral perfusion briefly falls. Review timing of falls relative to new drugs or dose changes, where the fall occurred, alcohol use, sleep, gait, vision, and prior episodes. Ask about standing symptoms and measure or obtain relevant positional blood pressure when appropriate. Identify each medicine's indication and ongoing benefit before changing it; abrupt withdrawal of some sedatives can itself cause harm. A safer plan may involve reducing a sedating burden, adjusting timing or treatment, and addressing environmental risks. Agree on who will make changes and how falls, alertness, and the treated condition will be monitored.
Worked example: An older patient fell while walking to the bathroom after starting a night-time benzodiazepine. They also feel light-headed when standing after a morning blood pressure medicine. Review the fall timing, sedative effects, standing symptoms, other drugs, and actual blood pressure pattern. Coordinate a cautious plan for the sedative and possible postural effects, then monitor both falls and the conditions the medicines treat.
Watch the distinction: Attributing the fall to age alone misses modifiable risks. Stopping every suspected medicine abruptly can create withdrawal or loss of disease control.
19. Protect seizure control
Stable seizure control depends on consistent exposure to an effective antiseizure medicine. Several missed doses can lower drug concentrations enough to permit a breakthrough seizure, although illness, sleep loss, interactions, and other causes also need review. Determine the exact medicine, formulation, last dose, length of interruption, seizure description, injury, and current mental state. A prolonged seizure, repeated seizures without recovery, or injury requires emergency care. Do not advise making up multiple missed doses at once; the safe restart plan depends on the medicine and interruption. Confirm the cause of the supply gap and arrange continuity, considering an authorized supply route or therapeutic plan. Changes between formulations can alter how a drug is delivered, so verify the product carefully. Follow-up should assess both seizure recurrence and reliable access.
Worked example: A patient previously seizure-free reports a seizure after missing three days of their antiseizure medicine because the pharmacy could not obtain it. The gap plausibly reduced protection but does not prove the only cause. Check recovery and injury, arrange prompt clinical review, verify the exact product and last dose, and coordinate an appropriate restart and supply plan. Do not instruct the patient to take three days of doses together.
Watch the distinction: A supply interruption is a plausible trigger, not a complete diagnosis. Automatically doubling or accumulating missed antiseizure doses may introduce toxicity without restoring safe control.
20. Assess reflux beyond symptom relief
Uncomplicated reflux may respond to suitable self-care and acid suppression, but repeated purchases should prompt reassessment of the diagnosis and ongoing need. Ask about symptom frequency, relation to meals or lying down, medicines that may irritate the upper gastrointestinal tract, and how the acid-suppressing product is taken. Acid suppression reduces acidity; it does not explain why swallowing has become difficult. Progressive dysphagia, food sticking, bleeding, unintended weight loss, or persistent vomiting are alarm features that call for medical assessment. Determine whether swallowing difficulty involves solids, liquids, or both, and whether the patient can currently manage food and fluids. Avoid simply increasing a product while an alarm feature remains unexplained. Once the cause is assessed, review whether the current medicine, timing, and duration still fit the patient's condition and goals.
Worked example: A patient has bought an acid-suppressing product several times and now says solid food sometimes sticks when swallowing. Ask whether liquids also stick, when this began, and whether there is weight loss or bleeding. Difficulty swallowing is an alarm feature, so arrange medical assessment rather than escalating self-treatment. Review the current product and use, but do not assume acid suppression resolves the new symptom.
Watch the distinction: Reflux symptoms do not make new swallowing difficulty routine. Repeatedly supplying stronger acid suppression can postpone assessment of a problem that needs a different investigation.
21. Assess medicines in pregnancy
Pregnancy changes the assessment of a medicine, but it does not erase the need to treat disease. Start with the condition, its severity, and what could happen to the pregnant patient and fetus if treatment stops. Then identify the exact medicine, dose, route, reason for use, gestational stage, and available evidence about exposure at that stage. A medicine with systemic effects may present a different question from a locally acting treatment, while a medicine essential for disease control may offer a substantial maternal benefit. Ask whether an effective option with better pregnancy safety evidence is available, and consider the risk of destabilizing a well-controlled condition during a switch. Include the patient’s priorities and arrange monitoring appropriate to the condition. The NAPRA pharmacist competencies support patient-specific assessment and collaborative care planning.
Worked example: A patient who is eight weeks pregnant plans to stop levothyroxine because the label mentions pregnancy. She takes it for hypothyroidism and has been stable. Stopping could allow thyroid hormone levels to fall, so the pharmacist advises against an abrupt stop, confirms her actual regimen and recent thyroid results, and coordinates timely review of thyroid function and treatment with her prenatal care team. The plan weighs continued treatment against the risk of untreated hypothyroidism.
Watch the distinction: Assuming every medicine should stop when pregnancy begins overlooks harm from untreated disease. Assess the particular medicine, exposure timing, available alternatives, and the patient’s condition first.
22. Check paediatric dose and formulation
A weight-based calculation answers only how much a stated order delivers. It does not establish that the ordered dose, interval, or medicine is appropriate. Confirm a current weight in kilograms, determine whether the instruction is in mg/kg per dose or mg/kg per day, and keep those units visible throughout the calculation. For a daily dose divided into administrations, calculate the daily amount before dividing; for a per-dose order, multiply directly by weight. Next check the intended indication, route, frequency, maximum permitted by the case information, kidney or liver concerns, and whether the available concentration permits accurate measurement. Convert milligrams to millilitres using the concentration actually on the bottle. A suitable oral syringe and a clear caregiver demonstration matter because a correct calculation can still become an inaccurate administered dose.
Worked example: A hypothetical order specifies 8 mg/kg per dose for a child weighing 20 kg. The amount is 8 mg/kg × 20 kg = 160 mg per dose. A liquid containing 40 mg/mL requires 160 mg ÷ 40 mg/mL = 4 mL per dose. The pharmacist checks that the ordered frequency and 160 mg dose fit the stated indication and product, then supplies a syringe marked to measure 4 mL.
Watch the distinction: A mathematically correct 4 mL answer does not validate the regimen. Confusing mg/kg per day with mg/kg per dose can multiply the intended exposure.
23. Review therapy in frailty
Frailty changes the balance between a medicine’s expected benefit and its immediate harms. Lower physiologic reserve can make sedation, postural dizziness, dehydration, or anticholinergic effects more consequential, even when a medicine was once tolerated. Review the reason each drug was started, current benefit, treatment duration, kidney function when relevant, recent changes, and the patient’s goals. Strong anticholinergic effects can impair attention, cause constipation or urinary retention, and contribute to confusion and falls. A new symptom may therefore be a medication problem rather than a new disease requiring another prescription. Compare continuing, reducing, replacing, or stopping the suspected drug, while accounting for withdrawal or recurrence when applicable. Agree on what symptom will be followed and when the patient or caregiver should seek reassessment.
Worked example: An older patient with frailty becomes confused after beginning diphenhydramine as a sleep aid. Their other medicines have not changed, and a caregiver reports daytime drowsiness and a recent fall. The timing and anticholinergic effects make diphenhydramine a plausible contributor. The pharmacist assesses urgent causes of new confusion, arranges prompt clinical assessment, and discusses stopping the sleep aid and using safer sleep measures with the patient and care team.
Watch the distinction: Adding a medicine for confusion before reviewing the drug list can compound harm. New cognitive symptoms call for assessment of acute illness and medication effects.
24. Assess substance use without assumptions
Ask about alcohol, tobacco, cannabis, and other substances as routinely as you ask about prescription and non-prescription medicines. Neutral questions about what, how much, when, and why a person uses them yield better safety information than labels or assumptions. The relevant interaction may be pharmacodynamic: alcohol and a sedative can both impair alertness and coordination without either changing the other’s blood concentration. Substance use can also change adherence, sleep, symptoms, and the interpretation of an adverse effect. Establish the actual pattern, including recent changes, and ask about driving, falls, and other immediate risks. Explain the specific concern in plain language, then work with the patient on a feasible plan for the underlying symptom and any support they want. Respectful enquiry makes later disclosure more likely.
Worked example: A patient taking a prescribed night-time sedative says they drink wine each evening. The pharmacist asks how many drinks, their timing relative to the dose, and whether the patient has felt drowsy or fallen. Both agents can reduce alertness, so the pharmacist explains the combined impairment risk, advises against taking them together, and arranges a discussion of safer sleep treatment that fits the patient’s circumstances.
Watch the distinction: A patient’s disclosure of alcohol use is clinical information, not proof of misuse. The useful response is to establish the pattern and address the specific combined risk.
25. Predict meaningful drug interactions
Drug interactions arise through different mechanisms, and that distinction guides what to check. A pharmacokinetic interaction changes absorption, metabolism, transport, or elimination, potentially changing a drug’s concentration. A pharmacodynamic interaction changes the combined effect at the body level, even when concentrations stay the same. Two agents that impair clotting or injure the gastrointestinal lining can raise bleeding risk by the latter route. Start with the patient’s indication and all medicines, including products bought without a prescription. Then assess the likely severity, dose and duration of exposure, patient risk factors, and available alternatives. Decide whether to avoid the combination, adjust treatment, or monitor a defined outcome. Warning signs such as black stools or persistent bleeding require urgent assessment. A database alert becomes useful only after this patient-specific interpretation.
Worked example: A patient taking apixaban for atrial fibrillation buys ibuprofen for knee pain. Ibuprofen can irritate the gastrointestinal tract and impair platelet function, adding bleeding risk without necessarily raising apixaban concentration. The pharmacist asks about previous bleeding and current symptoms, advises against starting the ibuprofen, and discusses non-drug measures and an appropriate alternative pain plan. Black stools or vomiting blood would require urgent assessment.
Watch the distinction: No change in anticoagulant concentration does not mean no interaction. Additive effects on bleeding can be clinically important even when drug levels are unaffected.
26. Investigate suspected adverse effects
Causality assessment begins with a timeline. Record when the medicine began, any dose change, when symptoms started, and what happened with missed or stopped doses. A biologically plausible reaction that follows exposure deserves attention, but timing alone cannot prove the drug caused it. Consider infection, foods, other new products, and whether similar symptoms occurred before. Assess severity first: breathing difficulty, mucosal involvement, extensive blistering, or systemic illness changes the urgency. If it is safe and clinically appropriate to stop or change a suspected medicine, subsequent improvement can strengthen the hypothesis, although resolution may also occur for other reasons. Avoid deliberately re-exposing someone after a potentially serious reaction. Document the drug, reaction features, timing, severity, and uncertainty so later treatment decisions use a useful history rather than a vague allergy label.
Worked example: A patient develops an itchy rash two days after starting a new antibiotic. Their long-term medicines are unchanged. The pharmacist asks about breathing symptoms, mouth sores, fever, rash spread, and other new exposures. With no severe features reported, the new antibiotic is a plausible cause, so the pharmacist promptly coordinates assessment and an alternative treatment if the infection still needs one. The record captures the timing and exact reaction rather than merely saying “allergy.”
Watch the distinction: A rash after a new drug is suspicious, but sequence alone is not proof. Check severity and competing causes, and record what is known rather than assigning certainty.
27. Match devices to patient ability
A medicine can fail because the patient cannot use its device effectively. Observe the whole task: preparation, grip, vision, breathing pattern, actuation, dose confirmation, and cleaning or storage. For a pressurised metered-dose inhaler, poor timing can send much of the spray to the mouth instead of the lungs. A spacer may reduce the coordination demand when appropriate. A dry-powder device poses a different challenge because the patient must generate sufficient inspiratory flow. Demonstrate the specific device, ask the patient to show each step, and correct the point of failure before judging the medicine ineffective. Check that the patient understands when to use it and can repeat the technique at home. Demonstration and teach-back are also useful skills to practise with the Part II OSCE guide.
Worked example: A patient with asthma says their metered-dose inhaler does nothing. On demonstration, they breathe in fully before pressing the canister. The pharmacist shows them to prepare the inhaler, begin a slow inhalation while actuating, and continue inhaling as instructed for that device. The patient then demonstrates the sequence correctly. If coordination remains difficult, the pharmacist assesses whether a suitable spacer would help and follows up on symptom control.
Watch the distinction: Persistent symptoms do not automatically mean the drug is ineffective. An unusable device or incorrect technique may prevent an adequate dose from reaching its target.
28. Find the cause of missed doses
A refill gap indicates that medicine may not have been available, but it does not explain why doses were missed. Ask without blame how the patient actually takes it and what gets in the way. Separate memory problems from adverse effects, cost, transportation, difficulty opening packaging, uncertainty about benefit, and a deliberate choice to stop. Each cause calls for a different intervention. A reminder may help someone who forgets despite having the medicine; it will not solve a supply barrier or an intolerable adverse effect. Check how long treatment has been interrupted and whether restarting the previous regimen needs clinical assessment, particularly for medicines where an interruption changes safety. Build a practical access plan with the patient and confirm when the next supply and follow-up will occur.
Worked example: A patient’s refill history suggests a two-week gap in blood pressure treatment. They explain that the pharmacy is far away and their usual ride was unavailable; they wanted to continue the medicine. The pharmacist confirms the last dose and checks for symptoms, then arranges an accessible supply option and a review of blood pressure after treatment resumes. A calendar reminder alone would leave the actual barrier untouched.
Watch the distinction: Labelling every refill gap as forgetfulness leads to the wrong intervention. Ask what happened before choosing reminders, delivery, a simpler regimen, or an adverse-effect review.
29. Set a measurable care plan
A care plan is useful when the patient can tell what success looks like and who will do each step. State the goal using a measure relevant to the condition, with a timeframe and a case-specific target when one is supplied. Specify the treatment action, who will perform it, and how benefit and harm will be monitored. For home blood pressure, measurement technique matters: use a suitable cuff, a consistent position and timing, and a record that preserves individual readings rather than a single memorable value. Agree on who reviews the record and what findings call for earlier contact. Incorporate the patient’s preferences and ability to carry out the plan. The target is a decision aid; symptoms, adverse effects, and quality of life still matter when deciding whether therapy is working.
Worked example: In a hypothetical case, the agreed home blood pressure goal is an average below 135/85 mmHg over the next four weeks. After a treatment change, the patient will take and record readings using the same validated device and agreed technique. The pharmacist will review the dated log and dizziness symptoms at four weeks, while the prescriber will assess any needed treatment change. New severe symptoms prompt earlier assessment rather than waiting for the scheduled review.
Watch the distinction: “Check blood pressure later” leaves the patient without a measurable task or review point. State the case goal, recording method, responsible reviewer, and timing.
30. Revise care after follow-up
Follow-up tests the whole care plan: intended benefit, adverse effects, actual use, and progress toward the patient’s goal. Compare current symptoms and measurements with the baseline and planned target. Establish whether a new problem began after treatment, whether it has another cause, and how much it affects daily life. Dizziness after a blood pressure medicine may reflect low blood pressure, a postural drop, dehydration, another medicine, or an unrelated condition. Ask about timing, falls, fluid intake, and missed doses; obtain appropriate seated and standing measurements when feasible. A treatment can improve the original symptom yet still be unacceptable. Decide with the patient whether to continue, change, or investigate further, and set a new review point. Severe symptoms or injury warrant more urgent assessment.
Worked example: Two weeks after a new blood pressure medicine, a patient reports fewer headaches but dizziness on standing. Their home log shows lower readings than before treatment, and they nearly fell yesterday. The pharmacist asks when doses and symptoms occur, reviews other medicines and hydration, and arranges prompt assessment of seated and standing blood pressure. The care team considers adjusting therapy while preserving blood pressure control, with follow-up for both readings and dizziness.
Watch the distinction: Improvement in one target does not establish overall success. Troublesome harm, such as near falls, must be weighed against benefit and may require revising treatment.
Providing Care: Distribution
31. Validate a prescription
Prescription validation asks whether the order can be trusted, understood, and acted on safely. Confirm the patient, drug, strength, dosage form, directions, quantity where needed, date, and prescriber identity. Assess authenticity and whether the prescriber is authorized for the order under the applicable provincial or territorial rules. Then perform the pharmacist’s therapeutic review: indication, patient factors, dose, interactions, and ability to use the product. An unclear strength is consequential because choosing one from the shelf would create a new order rather than interpret the authorized one. Clarify the ambiguity with an appropriate source, record the confirmed instruction, and only then prepare the medicine. The PEBC pharmacist blueprint includes prescription review within distribution care; technical completeness and patient-specific appropriateness both matter.
Worked example: A prescription names a patient and amlodipine but the handwritten strength could be read as either 5 mg or 10 mg. The patient’s old profile lists 5 mg, yet the prescriber may intend a change. The pharmacist verifies the order’s source, contacts the authorized prescriber for the intended strength and directions, records the clarification, and assesses the resulting regimen before dispensing. The old profile alone cannot settle the ambiguity.
Watch the distinction: A prior prescription is useful context, not permission to guess an unreadable new strength. Confirm the intended order before selecting stock or printing a label.
32. Review a changed prescription
A changed prescription can represent titration, replacement, duplication, or an unintended entry. Compare the new order with the active regimen, refill history, clinical reason, and any communication from the prescriber. Ask what the patient has actually been taking, since an active record does not prove current use. Identify whether the new strength replaces the old one, adds to it, or begins on a future date. Clarify unresolved conflicts before supply, and update the profile so future refills do not revive a discontinued dose. The pharmacist must also assess whether the new regimen is therapeutically suitable for this patient, including expected benefit, adverse effects, and monitoring. This is more than matching numbers: two individually valid prescriptions can be unsafe when used together.
Worked example: A patient has refills for metoprolol 25 mg tablets and brings a new order for 50 mg tablets. They say the prescriber discussed increasing the dose but cannot recall when to start. The pharmacist confirms with the prescriber that the 50 mg regimen replaces the 25 mg regimen immediately, then checks the patient’s pulse, symptoms, and other medicines as relevant. The old refills are marked discontinued, and the patient receives clear transition instructions.
Watch the distinction: An active refill does not prove that two strengths should be taken together. Resolve whether the change replaces or supplements the old regimen before dispensing.
33. Calculate quantity and days’ supply
Calculate quantity from the directions using units at every step: units per administration × administrations per day × number of days. Reverse the calculation to check days’ supply: quantity ÷ units used per day. This works for a fixed schedule, provided the directions do not change during the interval. A taper, alternating schedule, or loading phase must be split into segments and summed. For an as-needed medicine, the maximum permitted frequency gives only a minimum possible days’ supply if every allowed dose is used; actual use may last longer. Confirm that the quantity, directions, and intended treatment duration agree before processing. You can apply the same arithmetic to the PEBC Pharmacist MCQ practice questions, while keeping clinical appropriateness separate from the calculation.
Worked example: A hypothetical prescription says one tablet twice daily for 28 days. The quantity is 1 tablet/dose × 2 doses/day × 28 days = 56 tablets. Checking backward, 56 tablets ÷ 2 tablets/day = 28 days. If the same directions were “twice daily as needed,” 56 tablets would last at least 28 days at the maximum stated use, but could last longer if fewer doses were taken.
Watch the distinction: Dividing quantity by a fixed daily rate for an as-needed order treats possible use as actual use. State the assumption and avoid claiming an exact duration.
34. Calculate liquid volume safely
A liquid dose requires two separate checks: the prescribed mass must be appropriate, and the selected product must deliver that mass in a measurable volume. Use volume = ordered mass ÷ concentration, retaining units so mg divided by mg/mL produces mL. Confirm whether the label expresses concentration per millilitre or per larger stated volume before calculating. Different bottles of the same drug may have different strengths; using the wrong concentration can multiply or reduce the dose even if the arithmetic is correct. Check that the volume can be measured with an appropriate oral syringe and that directions specify the volume and route clearly. Recalculate after any product substitution, since the millilitre amount may change while the milligram dose stays constant. For higher-risk medicines, an independent calculation can catch unit or concentration errors.
Worked example: A hypothetical order calls for 300 mg per dose. The chosen oral liquid contains 50 mg/mL, so 300 mg ÷ 50 mg/mL = 6 mL per dose. Six millilitres × 50 mg/mL = 300 mg, which checks the result. The pharmacist confirms the bottle reads 50 mg/mL, provides an oral syringe that can measure 6 mL, and labels the dose in both milligrams and millilitres.
Watch the distinction: A correct millilitre calculation for one concentration is wrong for another. Check the actual bottle strength and recalculate whenever the selected product changes.
35. Handle verbal orders accurately
Verbal orders are vulnerable to sound-alike drug names, similar-sounding numbers, missing units, and transcription errors. Establish the caller’s identity and authority under the applicable jurisdictional rules, then capture the patient, medicine, strength, dosage form, directions, quantity, and other required details. Write or enter the order as received without filling gaps from assumption. Read the complete order back, spelling or clarifying uncertain drug names and stating numbers in a way that distinguishes them. An explicit confirmation resolves ambiguity; merely repeating an unclear phrase does not. Check the order against the patient’s record and its therapeutic purpose before processing. Record the clarification and source so another team member can see what was actually authorized. If the connection or caller cannot resolve a key detail, postpone processing until reliable confirmation is obtained.
Worked example: A caller requests a tablet strength that sounds like either fifteen or fifty milligrams. The pharmacist repeats the patient’s identity, generic drug name, dosage form, possible strength, directions, and quantity, then asks the caller to state and confirm the number clearly. The caller confirms 15 mg and the pharmacist records that clarification. The patient’s previous 15 mg prescription supports the result but was not used as a substitute for confirmation.
Watch the distinction: Hearing the same uncertain number twice is not verification. State the competing interpretations and obtain an explicit answer before entering or dispensing the order.
36. Select the correct product
Product selection requires matching more than the ingredient name and printed strength. Compare dosage form, route, concentration, release design, and any device features specified by the order. An immediate-release tablet delivers drug over a different time course from an extended-release tablet; equal milligrams do not imply equal exposure at every point in the day. A change can alter peak effects, duration, or the required dosing schedule. Similar packaging and shelf proximity make this error especially easy, so verify the full product description against the authorized prescription and physical stock. If the requested formulation is unavailable, assess clinically suitable alternatives and obtain any authorization required by the applicable jurisdiction before changing the order. The patient also needs to understand a genuine formulation change, particularly when directions differ.
Worked example: A prescription specifies metoprolol extended-release 50 mg once daily. The selected shelf bottle contains immediate-release metoprolol 50 mg tablets. Although the ingredient and strength match, the release characteristics and intended schedule do not. The pharmacist stops preparation, selects the ordered extended-release product if available, and verifies its label and directions. If it is unavailable, the pharmacist resolves an alternative regimen with the authorized prescriber before supply.
Watch the distinction: Matching ingredient and milligram strength does not make different release forms interchangeable. Check the formulation and dosing schedule before treating products as equivalent.
37. Compound non-sterile preparations safely
A non-sterile preparation begins with a suitable formulation, not merely a mass calculation. Verify the identity and quality of each ingredient, compatibility with the vehicle, intended concentration, equipment, and method of mixing. For a mass-by-mass preparation, total final mass equals the sum of ingredient masses when there is no material loss. Weigh accurately, incorporate the active ingredient by a method that promotes uniform distribution, and check the final preparation for visible defects or separation. Record lot information, quantities, method, quality checks, and the basis for storage and dating under the applicable standards. A compounded product must also be therapeutically appropriate and labelled for safe use. If the ingredients or method are unsuitable, a correct arithmetic result cannot rescue the preparation.
Worked example: A hypothetical formula calls for 100 g of a 2% mass-by-mass cream using 2 g of active ingredient and a compatible base, with no expected loss. The required base is 100 g − 2 g = 98 g. The pharmacist verifies ingredient identity and compatibility, weighs 2 g and 98 g, mixes until uniform, and checks that the final mass is 100 g before packaging and recording the preparation.
Watch the distinction: Subtracting 2 g from 100 g solves only the mass balance. Compatibility, uniform mixing, quality checks, and suitable packaging still determine whether the preparation is safe.
38. Recognize specialized compounding risk
An injectable preparation requires control of microbial and particulate contamination because it bypasses barriers that protect against an oral or topical product. Starting with sterile components does not make the final preparation sterile: transfers, containers, air, and handling can introduce contamination. Appropriate facilities, equipment, validated procedures, trained personnel, and quality checks are needed for aseptic work. Hazardous ingredients add a separate risk of occupational and environmental exposure, which requires controls for handling and containment. First classify the request by route and ingredient hazards; then determine whether the setting and staff have the required capability under applicable standards. If they do not, arrange preparation through an appropriately equipped service and maintain continuity of patient care. Do not assign an invented beyond-use date to an unfamiliar formulation.
Worked example: A hospital requests an injectable preparation made from sterile vials. A community pharmacy has equipment for routine non-sterile creams but no qualified aseptic preparation area. The pharmacist recognizes that vial sterility alone does not protect the final injection during manipulation. They confirm the clinical need and timing, then arrange supply through an appropriately equipped sterile compounding service, communicating the required formulation and delivery plan to the care team.
Watch the distinction: Sterile starting ingredients do not guarantee a sterile finished injection. Each transfer and container can introduce contamination, so aseptic capability must cover the whole process.
39. Package and label for safe use
Packaging protects a medicine from conditions that can change its quality, while the label translates the authorized order into usable instructions. Check whether the product needs protection from light, moisture, contamination, or breakage, and whether the container suits the patient’s ability to open and use it. A liquid label should state the measured volume, route, frequency, and any essential preparation instruction rather than only “take daily.” If the concentration changes, the volume instruction must be reviewed because the same milligram dose may require a different number of millilitres. Confirm that auxiliary information is relevant and understandable; too many competing warnings can obscure the critical instruction. Before release, compare the packaged product and label with the order and assess whether the patient or caregiver can measure and administer it accurately.
Worked example: A light-sensitive oral liquid is prepared in a clear bottle. The authorized order is 200 mg by mouth once daily from a 40 mg/mL product, but the label says only “take daily.” The dose volume is 200 mg ÷ 40 mg/mL = 5 mL. The pharmacist selects a light-protective container, confirms product compatibility, and changes the label to specify 5 mL by mouth once daily before final verification.
Watch the distinction: A label with the right drug name can still be unsafe. An unspecified liquid dose or unsuitable container can lead to administration errors or loss of quality.
40. Verify the finished product
Final verification is an independent comparison of the finished package with the authorized prescription and the product actually selected. Use a consistent sequence: patient, ingredient, strength, dosage form, quantity, directions, container, and visible product quality. Read the stock container and inspect the dispensed units rather than relying only on the computer record or printed label. This catches errors introduced during selection, counting, packaging, or labelling. A technically correct package also needs the pharmacist’s therapeutic assessment completed before release. If a mismatch appears, stop the product from reaching the patient, determine which step was wrong, correct it, and repeat verification of the finished result. A check that merely confirms one label matches another can miss the most important error: the contents differ from both.
Worked example: The prescription and printed label specify 10 mg tablets, but the stock bottle used during filling contains 20 mg tablets. The pharmacist compares the physical tablets and source bottle with the authorized order, detects the mismatch, and stops release. The 20 mg tablets are removed, the correct 10 mg product is selected and counted, and the completed package undergoes a fresh final check before it can be supplied.
Watch the distinction: A label that matches the prescription does not prove the tablets inside match. Inspect the physical product and its source container during the final check.
41. Release to the right patient
A prepared package is ready for release only when the pharmacist can establish three separate things: the prescription was assessed for therapeutic appropriateness, the finished product passed its technical and quality checks, and the patient received the consultation or education needed for safe use. A correct label cannot compensate for an unresolved interaction, and a sound clinical decision cannot compensate for the wrong tablets in the container. At handover, ask for an identifier independent of the surname, such as the patient's date of birth, and compare it with the prescription and package. Confirm that the person collecting it has an appropriate basis to receive it and that counselling reaches the patient or caregiver who will use the medicine. If any check remains incomplete, hold the package until it is resolved. The NAPRA pharmacist competencies place these release decisions within distribution care.
Worked example: Two patients named Chen have prescriptions awaiting collection. One package is labelled for Mei Chen, born 14 April 1964; the person at the counter gives the same surname but a different date of birth. The pharmacist keeps the package, locates the correct record and confirms that its therapeutic and technical checks are complete. Counselling is then provided for the medicine actually supplied.
Watch the distinction: A shared surname is not adequate identification. Releasing a correctly filled prescription to the wrong person still exposes that person to harm and breaches confidentiality.
42. Protect inventory integrity
Inventory decisions affect whether a dispensed medicine retains its identity, strength and quality. Record the product, lot, expiry, storage location and relevant movement so a recall can be traced from stock to patients who received it. For refrigerated stock, an excursion is a question about actual temperature and duration, not simply whether the refrigerator feels cold now. Isolate affected units and reconstruct the exposure from monitoring records; obtain product-specific stability advice before deciding whether they remain usable. During a shortage, distinguish a supply problem from a therapeutic substitution, which requires assessment of formulation, dose equivalence and patient needs. A controlled-substance count mismatch requires reconciliation of transactions and physical stock, with escalation and reporting under applicable requirements. These routes differ, but each prevents uncertain stock from quietly returning to supply.
Worked example: A refrigerator alarm occurred overnight, but its temperature log has a four-hour gap. The pharmacist separates the affected insulin stock, records the lots and estimates the exposure from available readings and alarm times. They seek product-specific stability information before release, check unaffected stock for patients due today, and document the final stock decision. A normal temperature at opening does not settle the gap.
Watch the distinction: Returning stock to sale once the refrigerator cools ignores possible earlier damage. The quality decision depends on the product and its documented exposure.
Knowledge and Expertise
43. Ask a focused clinical question
A useful evidence search begins with the decision the patient faces. Specify the population and relevant features, the proposed intervention, the realistic comparator, and outcomes that matter to the patient. This PICO structure prevents a search for a drug name from returning an attractive but irrelevant result. Include the reason for considering change, such as dizziness, kidney disease or a difficult device. Choose outcomes that represent both benefit and harm: symptom control, falls, hospital visits or treatment burden may matter more than an isolated laboratory marker. Then identify the evidence type suited to the question, assess its quality and determine whether participants resemble this patient. The question can be revised if the first search reveals a different comparator or a clinically important subgroup. A PEBC pharmacist study guide can help place this reasoning alongside other care decisions.
Worked example: A patient with hypertension has controlled readings but falls after standing and feels dizzy since a medicine change. The pharmacist asks: in older adults with treated hypertension and postural symptoms, how does an alternative regimen compare with continuing the current one for blood pressure control and falls? Evidence limited to lowering seated blood pressure cannot answer the fall-risk part of that question.
Watch the distinction: Searching only the medicine name may produce strong evidence for the wrong question. Define the patient, comparison and outcomes before judging a result relevant.
44. Judge evidence quality
Evidence quality is about how confidently a result can support the patient decision, not how impressive its conclusion sounds. Start with design: random allocation can reduce systematic differences between groups, while observational comparisons are especially vulnerable to confounding. Then inspect allocation, blinding where feasible, missing data, selective reporting and whether analysis preserved the assigned groups. Ask whether the outcome is meaningful: fewer admissions or less pain is more direct than improvement in a surrogate laboratory value. Check the size and precision of the effect, including the confidence interval; a wide interval may allow both useful benefit and little benefit. Finally, examine applicability to the patient's age, comorbidities, concurrent medicines and ability to follow the intervention. A large study with irrelevant participants may still answer this patient's question poorly.
Worked example: A small unblinded study finds a better inflammatory marker after a medicine change, but it reports no symptoms or admissions and loses many participants to follow-up. A larger randomized trial measures hospital visits and adverse effects in patients similar to yours. The second study better informs care, while its own methods and precision still need checking before applying its result.
Watch the distinction: A statistically significant surrogate result is not automatically a patient benefit. Bias, missing outcomes and an unlike patient population can weaken the conclusion.
45. Interpret absolute benefit
Absolute benefit translates an event-rate difference into the number of people affected over a stated period. Subtract the treated event risk from the control risk to obtain absolute risk reduction. Divide 1 by that reduction expressed as a proportion to obtain number needed to treat, or NNT; conventionally round an NNT up to a whole person. Relative risk reduction divides the absolute difference by the control risk and often sounds larger, but it cannot tell a patient how many events are prevented without baseline risk. Keep the outcome and follow-up time attached to every figure. An NNT derived from two-year data is not a lifetime value, and an average trial estimate may change when baseline risk differs. Also check whether the compared groups had the same observation period and whether the reported rates refer to patients or repeated events.
Worked example: In a hypothetical two-year study, 10 of 100 untreated patients and 6 of 100 treated patients have the stated event. Absolute reduction is 10% − 6% = 4 percentage points, or 0.04. NNT is 1 ÷ 0.04 = 25 patients treated for two years to prevent one event on average. Relative reduction is 4% ÷ 10% = 40%.
Watch the distinction: Calling the 40% relative reduction a 40-per-100 absolute benefit exaggerates the result. Here the observed difference is four events per 100 patients over two years.
46. Interpret harm alongside benefit
A treatment can lower one risk while raising another, so express both effects on the same denominator and over the same follow-up period. Calculate absolute risk reduction for the desired outcome and absolute risk increase for the harm. Their reciprocals give NNT and number needed to harm, but these counts cannot simply be subtracted: outcomes differ in severity, reversibility and importance to the patient. Determine whether a reported adverse event is truly treatment related, whether competing risks were measured and whether the person has a different baseline bleeding or event risk from trial participants. Present the numbers plainly, then ask which outcomes the patient most wants to avoid. Professional judgment combines the evidence with contraindications, monitoring feasibility and the person's goals. A favourable average balance does not settle every patient's decision.
Worked example: In a hypothetical two-year comparison, treatment prevents 4 serious events and causes 2 major bleeds per 100 patients. Benefit is 4/100 = 0.04, so NNT is 25; excess harm is 2/100 = 0.02, so number needed to harm is 50. Both describe averages over two years. A patient with a prior bleed needs individualized risk assessment before choosing.
Watch the distinction: NNT of 25 and number needed to harm of 50 do not prove treatment is twice as valuable. The outcomes and individual risks differ.
47. Apply evidence to comorbidity
Applying a study result requires comparing its participants and care setting with the person in front of you. Review eligibility criteria, baseline event risk, kidney and liver function, age, comorbidities, concurrent medicines, treatment intensity and follow-up. Excluding a subgroup may leave efficacy uncertain and can be especially important when the drug or its metabolites are cleared through the affected organ. Subgroup findings can help, but small groups produce imprecise estimates and many comparisons raise the chance of misleading differences. Look for pharmacokinetic evidence, safety data and guidance specific to the comorbidity, then determine whether monitoring or an alternative makes treatment reasonable. Explain where evidence is indirect rather than presenting the trial average as a personal forecast. This is an applicability question even when the original trial was carefully conducted.
Worked example: A trial of a new medicine reports fewer admissions, but excluded patients with advanced kidney disease. Your patient has advanced kidney disease and uses another medicine that may affect the same adverse-effect risk. The pharmacist cannot transfer the average trial benefit and safety estimate unchanged. They review kidney-specific data, the interaction and available alternatives before recommending a plan with appropriate follow-up.
Watch the distinction: A well-run trial does not guarantee applicability to excluded patients. The missing subgroup evidence matters most when the condition changes exposure or harm.
48. Resolve conflicting recommendations
When recommendations disagree, first check whether they answer the same clinical question. A medicine may be favoured after a documented cardiovascular event but discouraged for someone who has never had one. Compare populations, disease severity, outcome definitions, publication and evidence-review dates, and whether each recommendation is strong or conditional. A newer document is not automatically superior if it addresses a different setting or relies on weaker evidence. Identify the studies driving each recommendation and whether new benefit or harm data explain the difference. Next, map the patient's facts onto the relevant population, including age, bleeding risk, comorbidities and preferences. If uncertainty remains, communicate it and make a defensible decision with the care team and patient. The PEBC pharmacist blueprint identifies evidence-informed judgment as relevant to Part I.
Worked example: One guidance document recommends an antiplatelet medicine after myocardial infarction; another advises against routine use for primary prevention in older adults. Your patient had a myocardial infarction. The recommendations address different populations, so the secondary-prevention guidance is the relevant starting point. The pharmacist still assesses this patient's bleeding history, current therapy and goals before supporting continued treatment.
Watch the distinction: Choosing whichever document is newest can apply a primary-prevention recommendation to someone with established disease. Match the clinical question before comparing advice.
49. Explain an evidence-informed choice
An evidence-informed recommendation has four parts: the expected benefit, important harms, fit with this patient's circumstances, and a workable follow-up plan. Compare options using outcomes the patient values, then check contraindications, interactions, cost, access and the ability to use the formulation or device correctly. A treatment that works in a trial can perform poorly when the patient cannot operate its device or obtain regular refills. Explain the trade-off in everyday terms and make the reasoning visible: why this option, why now, and what would prompt a change. Ask the patient to describe their preference and practical concerns, because a reasonable choice depends on their goals. Document the decision and any uncertainty, then specify who will assess benefit and adverse effects. This turns research findings into care the person can actually follow.
Worked example: Two inhaled therapies have similar expected symptom benefit for a patient, but one uses a dry-powder device they cannot operate reliably despite teaching. The other uses a device they demonstrate correctly and can afford. The pharmacist recommends the usable option, explains that effective delivery depends on technique, and arranges a review of symptoms and device use after the change.
Watch the distinction: Equal average efficacy does not make two options interchangeable for an individual. Device ability, access and patient goals can change the best choice.
Communication and Collaboration
50. Confirm shared understanding
Understanding is an outcome of communication, not something established by a patient's nod. Begin with the patient's preferred language, what they already know, and what matters to them. Give a short explanation using familiar words and one or two key actions at a time; demonstrate a device when physical technique matters. Invite questions without implying that confusion is the patient's fault. Teach-back asks the person to explain or show the plan in their own words, so the pharmacist can detect a gap and teach again. For an inhaler, check preparation, inhalation, actuation where relevant and what to do after use. A qualified interpreter may be needed when language differences could affect consent or safe use. Record any remaining barrier and arrange help. PEBC Pharmacist MCQ practice questions can reinforce decisions about communication in patient scenarios.
Worked example: A patient says they understand a new maintenance inhaler, but describes using it only when breathless. The pharmacist explains its scheduled role, distinguishes it from the patient's reliever, then demonstrates the device. Asked to show the plan back, the patient initially skips preparation. After another demonstration, they perform the sequence correctly and state when each inhaler is used.
Watch the distinction: Asking “Do you understand?” and receiving “yes” does not confirm safe use. Teach-back reveals which instruction needs a clearer explanation or demonstration.
51. Communicate a care transition
A useful transition message lets the next provider act without reconstructing the entire admission. Identify the patient and care setting, the verified current regimen, what changed and why, and any discrepancy that remains unresolved. Include the source of clarification, significant allergies or adverse reactions, monitoring needs, who is responsible for each action and a review time. Separate facts from assumptions: a discharge order and a patient report can conflict, and the message should state how the conflict was resolved. Send it through an appropriate secure channel and confirm that a time-sensitive issue reaches the responsible person. The pharmacist also updates the patient-facing list so the patient and team work from the same regimen. Clear transfer of care reduces duplicate therapy, omission and conflicting instructions across settings.
Worked example: A discharge list says metoprolol 25 mg twice daily, while the older community record says 50 mg twice daily. The discharge prescriber confirms the lower strength was intentional because of dizziness. The pharmacist updates the active list, explains the new regimen to the patient, and tells the next provider who confirmed it and what blood-pressure and symptom review remains planned.
Watch the distinction: Forwarding both lists without identifying the intended dose leaves the discrepancy for someone else to resolve and may expose the patient to duplicate or incorrect treatment.
Leadership and Stewardship
52. Address barriers to community care
Missed therapy can reflect transport, housing, cost, language, disability or caregiving demands rather than a lack of motivation. Ask what happens between receiving a prescription and taking the medicine: getting to the pharmacy, paying, storing it, using the device and fitting doses into daily life. Then match support to the barrier. Delivery or synchronized refills may address transport; a social worker or community service may help with costs or stable storage; a different formulation may solve a dexterity problem. Check that the proposed arrangement is acceptable, reliable and within local service rules. Use scarce services thoughtfully by prioritizing those whose treatment interruption carries the greatest risk. Agree on who will make contact and when supply will be confirmed. This is a concrete public-health role because practical access determines whether effective therapy reaches patients.
Worked example: A patient has missed two monthly refills of an essential chronic medicine. They explain that the only bus route to the pharmacy was cancelled, while they still want treatment. The pharmacist checks current supply and clinical urgency, offers an available delivery arrangement, helps coordinate future refill dates, and confirms receipt. A reminder alarm would not repair the transport problem.
Watch the distinction: Labelling the patient nonadherent without asking about access may produce an ineffective intervention. Find the barrier before choosing the support.
53. Protect health during disruption
During a supply disruption, the pharmacist first determines who may run out, when, and what harm an interruption could cause. Verify physical stock and expected deliveries rather than relying on a computer balance alone. Prioritize continuity for patients with limited reserve, high-risk conditions or no suitable alternative, while avoiding unnecessary accumulation that worsens the shortage for others. Assess any substitute clinically: active ingredient, strength, formulation, route, administration method and monitoring may all matter. Coordinate changes with authorized prescribers or other services as needed, explain the temporary plan to patients, and record who will reassess it. Community emergencies also change the risk of disease transmission, so adapt handover and infection-prevention procedures to protect patients and staff. A supply plan is complete only when the patient can obtain and use the chosen therapy.
Worked example: A storm delays deliveries of an antiseizure medicine. The pharmacy verifies remaining stock, checks which patients will run out first and contacts the wholesaler and nearby services. One patient has only one day of supply, so the pharmacist arranges a clinically suitable continuity plan with the care team and confirms access. Stable patients with larger supplies receive updates and a review date.
Watch the distinction: Giving all remaining stock to the first requester can leave higher-risk patients without therapy. Triage requires verified supply, interruption risk and suitable alternatives.
Professionalism
54. Apply the local scope rule
A pharmacist's ability to perform a service depends on the province or territory, the specific activity, its conditions, and the pharmacist's own competence. Check what the local authority permits, whether training or authorization is required, whether the clinical situation fits the permitted category, and what documentation or communication is required. Legal authority alone does not establish clinical appropriateness: assess diagnosis or symptoms, history, medicines, contraindications, monitoring and follow-up. Conversely, clinical confidence cannot create legal authority. If the service is unavailable or outside scope, provide useful assessment and arrange an appropriate route to care rather than leaving the patient with an unexplained refusal. The national NAPRA competencies describe entry-to-practice abilities while directing practitioners to apply the rules of their jurisdiction.
Worked example: In a hypothetical province, a trained pharmacist may prescribe for a specified minor condition only after assessing listed exclusion features. A patient requests treatment but reports a symptom named as an exclusion in the case rule. The pharmacist does not prescribe under that authority, explains the concern, provides appropriate interim advice and arranges timely medical assessment. The case rule, rather than an assumed national permission, controls the decision.
Watch the distinction: A service being permitted somewhere in Canada does not authorize it everywhere. Confirm the local rule and its conditions, then assess whether this patient fits.
55. Protect privacy and consent
Medication information is sensitive because it can reveal diagnoses, treatments and personal circumstances. Before disclosure, identify the requester, the exact information sought, the purpose, and the patient's consent or another valid basis for sharing. A family relationship by itself does not prove authority; a caregiver involved in care may still need an appropriate basis for receiving details. Give only information relevant to the authorized purpose and use a private, secure channel. For consent to be meaningful, the patient should understand what will be shared, with whom and why, and have a chance to decline where applicable. Also distinguish asking someone to help contact a patient from telling them the patient's medication list. Record the basis for a significant disclosure and any restrictions the patient expresses. These steps preserve trust while still supporting necessary care coordination.
Worked example: A caller says they are a patient's adult child and asks for a full medication list. The record contains no consent or established decision-making authority. The pharmacist verifies the caller's identity but does not disclose the list. They contact the patient through an established channel to ask whether, and for what purpose, information may be shared, then document the patient's decision.
Watch the distinction: Knowing a patient's address or date of birth does not establish permission to receive their health information. Identity verification and disclosure authority are separate questions.
56. Manage conflicts of interest
A conflict of interest exists when a financial or personal interest could influence professional judgment or appear to do so. Identify the interest before recommending a product: incentives, ownership arrangements or a close relationship may all matter. Compare the options on indication, likely benefit, harm, patient preference, access and cost, using the same clinical standard regardless of revenue. Disclose a relevant interest when required, and consider whether another clinician should make the recommendation if independence cannot be maintained. A cheaper or higher-margin product is not automatically inappropriate; the issue is whether the recommendation is justified for this patient and explained honestly. Keep business discussions separate from the clinical assessment, and document the reasoning when a choice could reasonably be questioned. Transparency allows the patient to make an informed decision without hiding a competing interest.
Worked example: A pharmacy promotion rewards sales of a particular glucose-monitoring device. A patient has impaired vision and cannot read that device's display, but can use another available model. The pharmacist recommends the accessible model, explains its practical advantage and discloses the relevant incentive under applicable requirements. The choice follows the patient's ability to use the device, not the promotion.
Watch the distinction: An incentive does not make the promoted product the best choice. Ignoring a patient's ability or concealing a relevant financial interest can distort care.
57. Respect informed refusal
A capable patient can decline a recommended treatment even when the pharmacist believes it offers important benefit. First confirm that the person understands the condition, proposed benefit, material harms and likely consequences of declining, using language they can explain back. Explore the reason without pressure: adverse effects, cost, beliefs or a different goal may reveal an acceptable alternative. Assess whether urgency, impaired capacity or coercion changes the situation, following applicable requirements. Then respect the decision, document the discussion and offer a safety plan, including symptoms that warrant help and a time to revisit the choice. Keep access to future care open. Informed refusal is an ongoing conversation rather than a signed form alone; the patient may reconsider when circumstances change or new information becomes available.
Worked example: A patient with a documented cardiovascular condition declines a recommended preventive medicine because a previous medicine caused severe muscle pain. They can explain the expected benefit and the risk of declining. The pharmacist records the concern, discusses a different reasonable option with the care team, agrees on symptom follow-up and tells the patient how to seek help if their decision changes.
Watch the distinction: Refusal does not mean the pharmacist should end the relationship or quietly record “noncompliant.” Explore the concern, respect an informed choice and preserve follow-up.
58. Provide culturally safe care
Culturally safe care begins by asking how this individual wants to receive care, rather than predicting preferences from identity or background. Notice barriers the service may create, including language, inaccessible forms, cost, prior discrimination or lack of privacy. Use a qualified interpreter when important treatment or consent details could be misunderstood, speak directly to the patient and check understanding. Ask about prior experiences and what would make the encounter feel safer; listen without disputing the patient's account. Cultural humility means recognizing that the patient is the expert on their own experience and that the pharmacist may need to adjust the service. For Indigenous patients, awareness of historical and ongoing harms should inform respectful practice without turning any one person's identity into a clinical assumption. Agree on a practical plan and confirm the patient can access it.
Worked example: A patient asks for an interpreter and says an earlier pharmacy dismissed their concerns about adverse effects. The pharmacist arranges appropriate language support, invites the patient to describe the symptoms and what matters most, then reviews the medicine and options together. The patient explains the plan back through the interpreter, and the pharmacist records the agreed follow-up without making assumptions about their beliefs.
Watch the distinction: Assuming a patient's preferences from their culture can repeat the harm they described. Ask, listen and adapt the service to the person.
59. Respond to an incident or near miss
The first question after a dispensing error is whether the product reached the patient. If the wrong item is caught before release, it is a near miss; if it reached the patient, it is a medication incident even when no harm is yet apparent. Stop the process, secure the product and assess immediate patient risk. For an incident, establish what was supplied, whether it was taken and what clinical response is needed, then communicate transparently under applicable requirements. For either event, record the facts without blame and examine contributing conditions such as similar packaging, interruptions or a weak check. The goal is a control that prevents recurrence, not merely a reminder to be careful. Share learning with the team and verify that the corrected prescription is safely completed.
Worked example: A final check finds 20 mg tablets in a package labelled 10 mg before handover. The pharmacist holds it, confirms the authorized order, replaces the tablets and completes a fresh verification. Because it never reached the patient, this is a near miss. The team records the selection error and finds that both strengths were stored together in similar cartons.
Watch the distinction: Calling this harmless because the patient received nothing misses a useful warning. A near miss reveals a failure path that could reach another patient.
60. Improve a high-risk process
Repeated near misses point to a process condition worth changing. Define the error precisely, map where selection or verification can fail, and collect enough observations to identify a likely cause. Similar names, look-alike cartons, crowded shelves and interruption-prone steps may combine to produce one error pattern. Choose a control that changes the work itself, such as separating strengths, improving shelf labels or adding a focused verification step for the vulnerable product. Assign someone to implement it and a way to measure whether it works, using both errors and near misses over a comparable period. Review for unintended effects, such as staff bypassing a cumbersome step or moving the confusion elsewhere. Share results with the team and revise the control if risk persists. Continuous improvement depends on feedback, not a single announcement.
Worked example: Over one month, staff catch three selections of the wrong strength from adjacent look-alike cartons. They separate the strengths, add clear shelf identifiers and require comparison with the stock label at selection. During the next comparable month, they track selections and near misses, not just dispensed errors. If confusion continues, they examine workflow and packaging rather than declaring success after rearranging shelves.
Watch the distinction: Telling staff to “be more careful” leaves the confusing shelf unchanged. A useful safety intervention changes the error pathway and checks its effect.
Official references and further reading
- PEBC complete current May 2026 pharmacist qualifying-exam blueprint with separate MCQ/OSCE weights
- NAPRA complete 2024 entry-to-practice professional competencies with pharmacist/technician columns preserved
- PEBC current blueprint interpretation and Canadian pharmacist scope
- PEBC current Part I MCQ examination period and delivery
- PEBC current Part I best-answer MCQ style, SI units and permitted formula/calculator references